Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation,The Journal of Clinical Investigation

当前位置： X-MOL 学术 › J. Clin. Invest. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation
The Journal of Clinical Investigation ( IF 15.9 ) Pub Date : 2023 , DOI: 10.1172/jci175369
Magnus T Dillon _{1,

2} , Jeane Guevara ₂ , Kabir Mohammed ₂ , Emmanuel C Patin ₁ , Simon A Smith ₃ , Emma Dean ₃ , Gemma N Jones ₃ , Sophie E Willis ₃ , Marcella Petrone ₄ , Carlos Silva ₄ , Khin Thway ₂ , Catey Bunce ₂ , Ioannis Roxanis ₁ , Pablo Nenclares ₁ , Anna Wilkins _{1,

2} , Martin McLaughlin ₁ , Adoracion Jayme-Laiche ₅ , Sarah Benafif ₅ , Georgios Nintos ₆ , Vineet Kwatra ₆ , Lorna Grove ₁ , David Mansfield ₁ , Paula Proszek _{1,

2} , Philip Martin ₇ , Luiza Moore ₇ , Karen E Swales ₁ , Udai Banerji _{1,

2} , Mark P Saunders ₈ , James Spicer ₆ , Martin D Forster ₅ , Kevin J Harrington _{1,

2}

Affiliation

BACKGROUND. Phase 1 study of ATRinhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738) in advanced solid tumors.

中文翻译：

在具有基因组缺陷和高炎症的肿瘤中，ceralasertib 对 ATR 抑制产生持久反应

背景。单独或联合放射治疗抑制ATR的第1 期研究(PATRIOT) 是口服 ATR（共济失调毛细血管扩张和 Rad3 相关）抑制剂 ceralasertib (AZD6738) 在晚期实体瘤中的首次人体 I 期研究。

更新日期：2024-01-17

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>